Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or ...
Approval is based on the Phase 3 KEYNOTE-859 Trial KIRKLAND, QC, April 19, 2024 /CNW/ -Merck & Co. (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab …